The female predominance in several autoimmune diseases suggests a role for sex steroid hormones in disease susceptibility. We therefore investigated to what extent sex hormones would influence immune responsiveness. We analyzed T helper type 1 (T H 1) and type 2 cytokine patterns, chemokine receptor expression (n ϭ 2 ϫ 10), and Ig levels (n ϭ 2 ϫ 25) in transsexual men and women before and after 4 months of cross-sex hormone administration. Antithyroperoxidase levels were compared between 186 transsexual males (treated Ͼ5 yr with estrogens) and 186 male controls.
S EVERAL LINES of evidence implicate sex steroids as
modulators of immune responses, but the in vivo mechanisms underlying this relationship are poorly understood (1) . A first important observation is the higher prevalence of most autoimmune diseases in females compared to males (2) . Second, women compared to men, have higher serum levels of IgM, IgG (3) (4) (5) (6) , and distinct autoantibodies such as IgG against the major microsomal antigen thyroperoxidase (TPO-Ab) (7) (8) (9) . Conversely, women compared to men, show a reduced antibody-dependent cell-mediated (10, 11) and natural killer (NK) cell cytotoxicity (12, 13) . Third, binding sites for sex steroids are present (14 -16) , and sex steroids can be metabolized in immunocompetent cells (17) (18) (19) , suggesting that sex steroids may affect leukocyte function directly. Fourth, experimental studies show that the course of autoimmune disease can be modulated by castration or administration of sex steroids, for example in chicken and murine models of autoimmune thyroid disease (20, 21) . Estrogen treatment in female or male mice as well as castration of male mice result in an increase in autoantibody levels (21) (22) (23) (24) (25) .
T helper cells can be divided into the reciprocally suppressive T helper type 1 (T H 1) and T H 2 subsets, which are defined by their profile of cytokine release and the type of response they elicit. Polarized T H 1 or T H 2 immune responses are associated, on the one hand, with protective immunity against certain intracellular bacteria and viruses or parasites, respectively, and, on the other hand, with certain autoimmune diseases or allergy. T H 1 cells produce interleukin-2 (IL-2), interferon-␥ (IFN␥), and, less specifically, tumor necrosis factor-␣ (TNF␣), stimulating cell-mediated immune responses, whereas T H 2 cells produce IL-4, IL-5, IL-10, and IL-13, which provide help for humoral immune responses (26, 27) , such as the production of IgE and IgG4 (28, 29) . The body distribution of these T cells is directed by the differential expression on the cell membrane of distinct sets of adhesion molecules and chemokine receptors. Chemokines are chemotactic cytokines produced by a wide variety of cells to attract the relevant leukocytes to sites of infection and inflammation (30, 31) . T H 1 and T H 2 cells express different chemokine receptor profiles; T H 1 cells seem to preferentially express the CC chemokine receptors, CCR1, CXCR3, and CCR5 (32) (33) (34) (35) , facilitating their selective migration into inflammatory lesions. The factors that influence chemokine receptor expression in vivo are still largely unknown.
Sex differences on cytokine production in vivo have not been reported to date; nevertheless, sex steroids seem to differentially affect T H 1 and T H 2 cytokine production. During pregnancy, the T H 1/T H 2 balance is skewed toward T H 2 (36) , thereby preventing rejection of the antigenically foreign fetus by a cell-mediated immune attack (37, 38) . The shift toward a T H 2 response may be triggered by increased circulating levels of 17␤-estradiol and progesterone (39) during pregnancy (40) . The in vitro influence of sex steroids on T cell cytokine production has been studied extensively (17, 18, 39, 41, 42) , showing complex and diverse effects, but human in vivo studies apart from pregnancy are scarce. Healthy transsexual males and females, therefore, provide a unique opportunity to study the in vivo effects of cross-sex steroid hormones on the immune system. Here we examine 1) the effects of either estrogens plus antiandrogens or testosterone on normal humoral and cellular immune parameters, and 2) the incidence of TPO-Ab expression in transsexual males treated for at least 5 yr with estrogens compared to male controls.
Subjects and Methods

Subjects in prospective study
We included 30 Caucasian male to female (M3 F; median age, 26 yr; range, 18 -45) and 30 Caucasian female to male (F3 M) transsexuals (median age, 23 yr; range, . The body mass index was 20 Ϯ 3 kg/m 2 (mean Ϯ sd) in M3 F and 23 Ϯ 5 kg/m 2 in F3 M transsexuals. All measurements were performed before and again after 4 (and 12) months of cross-sex hormone administration. In both groups gonadectomy had not yet taken place, but after cross-sex hormone administration their own sex steroid production was suppressed (Table 1) . M3 F transsexuals were treated with ethinyl estradiol (100 g/day; Lynoral, Organon, Oss, Netherlands) in combination with the antiandrogen cyproterone acetate (100 mg/day; Androcur, Schering AG, Weesp, The Netherlands). F3 M transsexuals were treated with either im testosterone esters (n ϭ 27; Sustanon, Organon; 250 mg/2 weeks) or oral testosterone undecanoate (n ϭ 3; Andriol, Organon; 160 mg/day). One F3 M transsexual reported intake of oral contraceptives 6 months before baseline. All other F3 M transsexuals had had regular menstrual cycles (28 -31 days) before cross-sex hormone administration. There was no evidence of autoimmune disease, immune deficiencies, chronic infection (e.g. with human immunodeficiency virus type 1), endocrine diseases, or use of other sex hormones for 3 yr or more before baseline. In all subjects, the body mass index (weight/height 2 ) was assessed, venous blood samples were taken in the morning between 0900 -1200 h after an overnight fast, and 24-h urine was collected (during the 24 h before blood sampling). For logistical reasons, most measurements were obtained in randomly chosen subgroups ( Table 1) . The investigation conformed with the principles outlined in the Declaration of Helsinki. Informed consent was obtained from all subjects, and the study was approved by the ethical review committee of the University Hospital Vrije Universiteit.
Endocrine measurements
Standardized RIAs were used to determine serum levels of testosterone (Coat-A-Count, Diagnostic Products, Los Angeles, CA), 5␣-dihydrotestosterone (after extraction, Intertech, Strassen, Luxembourg), dehydroepiandrosterone sulfate (DHEAS; Diagnostic Products), 17␤-estradiol (Sorin Biomedica, Saluggia, Italy), and, in 24-h urine samples, free cortisol (after extraction; Coat-A-Count, Diagnostic Products). To assess peripheral androgen activity, we measured serum 5␣-androstane-3␣,17␤-diol glucuronide (Adiol G) (43) by RIA (Diagnostic Systems Laboratories, Inc., Webster, TX). Immunometric luminescence assays were used to determine levels of FSH (Amerlite, Amersham Pharmacia Biotech, Aylesbury, UK) and LH (Amerlite). Immunoradiometric assays were used to measure serum levels of GH (Sorin Biomedica, Saluggia, Italy) and PRL (Biosource Technologies, Inc., Fleurus, Belgium).
Lymphocyte phenotyping
Measurements of lymphocyte subpopulations, cytokines, and chemokine receptors were performed in a random subgroup of 10 M3 F transsexuals (median age, 27 yr; range, 20 -41) and 10 F3 M transsexuals (median age, 26 yr; range, 18 -40) at baseline and after 4 months of cross-sex hormone administration. In fresh heparinized venous blood the numbers of CD3-, CD4-, CD8-, CD19-, and CD16/56-positive cells were analyzed on a FACStar Plus (Simulset, Becton Dickinson and Co., San Jose, CA). These lymphocyte subpopulations are expressed as percentages of the total number of lymphocytes.
Cytokine production in supernatants
IFN␥, IL-2, TNF␣, IL-4, IL-5, and IL-10 production by Ficoll isolated (Lymfoprep, Nycomed, Pharma AS, Oslo, Norway) and cryopreserved peripheral blood mononuclear cells (PBMC) was assessed in culture supernatants. To eliminate the effect of interassay variation, pre-and posttreatment samples from the same subject were analyzed in the same run. Therefore, 2.5 ϫ 10 6 PBMC/mL were cultured for 36 h in Iscove's Modified Dulbecco's Medium (BioWhittaker, Inc., Verviers, Belgium) supplemented with 10% human pooled serum (Central Laboratory Blood transfusion, Amsterdam, The Netherlands), 100 g/mL streptomycin, 100 IU/mL penicillin, and 2 g/mL anti-CD25 (CLB clone TB30). Cells were stimulated with 10 g/mL phytohemagglutinin (PHA; Murex Diagnostics Ltd., Dartfort, UK). Supernatants were stored at Ϫ80 C until analyses. All cytokines were measured by standard enzymelinked immunosorbent assay techniques with the following commercially available antibodies or kits: IL-2 and IFN␥ (Medgenix Diagnostics SA, Fleurs, Belgium); IL-4, IL-6, and TNF␣ (CLB compact enzyme-linked immunosorbent assay); and IL-10 (PharMingen, San Diego, CA).
Cytokines production at the single cell level
Staining of intracellular cytokines was performed as described by Jung et al. (44) . In brief, 2 ϫ 10 6 /mL thawed PBMC were incubated for 4 h in Iscove's Modified Dulbecco's Medium with the following supplements: 10% FBS (Integro, Leuvenheim, The Netherlands), penicillin, streptomycin, 20 ng/mL phorbol myristate acetate (Sigma, St. Louis, MO), 1 mol/L calcium ionophore (Sigma), and 3 mol/L monensin (Sigma). Subsequently, the cells were washed with phosphate-buffered saline/0.5% BSA (Roche Molecular Biochemicals, Mannheim, Germany) and stained with anti-CD3-RPE-Cy5 (DAKO Corp., Glostrup, Denmark) and anti-CD8-fluorescein isothiocyanate (anti-CD8-FITC; Becton Dickinson and Co.). After washing, the cells were fixed with 4% paraformaldehyde (Merck & Co., Inc., Darmstadt, Germany) and permeabilized with phosphate-buffered saline with 0.1% saponin (Merck & Co., Inc.), 0.5% BSA, and 10% human pooled serum. Intracellular staining was performed with anti-IFN␥-phycoerythrin (anti-IFN-PE), anti-IL-4-PE, and TNF␣-PE (PharMingen). Cells were analyzed on a FACStar Plus. The percentages of cytokine-producing cells were calculated within the CD3 ϩ , CD3 ϩ /CD8 ϩ , and CD3 ϩ /CD8 Ϫ cell fractions.
Chemokine receptor expression at the single cell level 
Serum levels of Ig (sub)classes
Measurements were performed in 25 M3 F transsexuals (median age, 29 yr; range, 18 -43) and 25 F3 M transsexuals (median age, 23 yr; range, 16 -37) at baseline and after 4 months of cross-sex hormone administration and in a subgroup of 13 M3 F and 13 F3 M transsexuals again at 12 months. Serum levels of IgA, IgM, IgG, and IgG4, the human equivalent of murine IgG1, were assessed by kinetic nephelometry [Array Protein System 360, Beckman Coulter, Inc., Fullerton, CA; interassay coefficients of variation (CV), Ͻ2.5%; interassay CV, Ͻ2.8%); IgE was assessed by fluoroimmunoassay (Pharmacia CAP System, Pharmacia & Upjohn, Inc., Bridgewater, NJ; intraassay CV, 6%; interassay CV, 6%).
Cross-sectional study of TPO-Ab expression
We included 186 M3 F transsexuals [median age, 43 yr; range, 21-70, because a sex difference in having TPO-Ab was found in the age range Netherlands; 0.625-2.5 mg/day; n ϭ 26), oral 17␤-estradiol (Progynova, Schering AG; 1-4 mg/day; n ϭ 7), or parenteral 17␤-estradiol (Progynon-depot, Schering AG, Berlin, Germany; 10/2 weeks; n ϭ 2). Some combined their treatment with the antiandrogen cyproterone acetate (Androcur, Shering; 2-100 mg/day; n ϭ 47) or spironolactone (Aldactone, Searle, Chicago, IL; 100 -200 mg/day; n ϭ 3). For every M3 F transsexual, a control male was selected of similar age (Ϯ2 yr), with a median age of 42 yr (range, 20 -72); they were M3 F transsexuals before hormone administration (n ϭ 131) and healthy nontranssexual males (n ϭ 55). Male controls were eugonadal by clinical and laboratory criteria: testosterone, 20 Ϯ 7 nmol/L (mean Ϯ sd); 17␤-estradiol, 86 Ϯ 24 pmol/L; and LH, 3.1 Ϯ 1.6 U/L. Serum PRL levels, available in 129 M3 F transsexuals and 131 male controls, were used as an index of estrogen administration. Serum TPO-Ab titers were assayed using the Mileniatest (Diagnostic Products) and titers of 10 IU/mL or more were considered positive.
Statistical analysis
Variables with distributions that were skewed to the right (cytokine levels and expression, chemokine receptor expression, Ig isotype levels) were logarithmically transformed before analysis to normalize their distributions. Antilogarithms of the transformed means were used to obtain geometric means and 95% confidence intervals (CI) of the means. Mann-Whitney tests for independent samples were used to compare baseline differences. Wilcoxon's signed ranks test was used to analyze the effects of cross-sex hormones after 4 months for all measurements as well as for comparisons of PRL and TPO-Ab levels between M3 F transsexuals and male controls. Spearman's correlation coefficients were used for intercorrelations. In the M3 F and the F3 M groups separately, an ANOVA for repeated measurements was used to analyze the effects of cross-sex hormones at three time points on Ig (sub)class levels as well as to compare at two time points the effects of estrogens plus antiandrogens with those of androgens. If values were below the lower limit of detection, the value of that lower limit was used for statistical calculations (for 17␤-estradiol, 90 pmol/L; for testosterone, 1.0 nmol/L; for 5␣-dihydrotestosterone, 0.1 nmol/L; for LH, 0.3 IU/L; for FSH, 0.5 IU/L; for IgE, 2 U/mL). A two-tailed P value of less than 0.05 was considered statistically significant. The software used was SPSS for Windows 8.0 (SPSS, Inc., Chicago, IL).
Results
Endocrine measurements
After estrogen plus antiandrogen administration to M3 F transsexuals, serum levels of total testosterone, 5␣-dihydrotestosterone, Adiol G, DHEAS, LH, and FSH were significantly suppressed, mostly to undetectable levels. The ethinyl estradiol that had been administered could not be detected by the assay used, but there were clear physical signs of estrogen effects in these subjects. Free cortisol excretion in 24-h urine samples and serum PRL levels showed a significant increase, whereas serum GH levels slightly increased (Table 1) .
After parenteral testosterone administration to F3 M transsexuals, the serum levels of total testosterone, 5␣-dihydrotestosterone, and Adiol G significantly increased, whereas serum levels of 17␤-estradiol, LH, and FSH levels were slightly, but significantly, suppressed. Serum levels of DHEAS, PRL, and GH as well as free cortisol excretion in 24-h urine samples did not change significantly (Table 1) .
Leukocytes and lymphocyte subpopulations
After estrogen plus antiandrogen administration to males, the mean number of leukocytes increased, whereas no change occurred after testosterone administration to females. There was a tendency toward a lower number of CD4 ϩ T cells (P ϭ 0.052) and a lower CD4 ϩ /CD8 ϩ ratio (P ϭ 0.08) in males compared to females (Table 1) . Upon cross-sex hormone administration there were no changes in either the total number of lymphocytes or the relative number of CD4 ϩ and CD8 ϩ T cells in male or in female transsexuals (Table 1 and Fig. 1 ). After estrogen plus antiandrogen administration to males, both absolute (data not shown; P ϭ 0.03) and relative numbers of NK cells decreased (P ϭ 0.01), whereas a slight increase was found in the absolute (data not shown; P ϭ 0.24) and relative number (P ϭ 0.11; Table 1 and Fig. 1) of B cells. Upon testosterone administration to females, changes in NK and B cells, were less obvious and did not reach statistical significance (Table 1 and Fig. 1) . However, the effects of estrogen plus antiandrogen were the opposite of those of testosterone (P ϭ 0.02 for NK cells and P ϭ 0.07 for B cells, for differences between M3 F and F3 M transsexuals by ANOVA for repeated measurements).
Production and intracellular expression of cytokines
Before hormone administration, males produced higher levels of IFN␥ upon PHA stimulation than females (P ϭ 0.02). The number of IFN␥-producing T cells also tended to be higher in males (P ϭ 0.07; Table 1 ). Upon hormone administration, no significant differences were found for individual cytokines, either in supernatants upon PHA stimulation or by intracellular staining, except for the PHA-stimulated production of TNF-␣, which increased significantly upon testosterone administration (P ϭ 0.03; Table 1 ). However, an overall shift toward a T H 1 phenotype, as evaluated by the PHA-stimulated production ratio of IFN␥ to IL-4, was found in females upon testosterone administration (P ϭ 0.008), whereas this T H 1 phenotype tended to be down-regulated in males upon estrogen and antiandrogen administration (P ϭ 0.14 and P ϭ 0.001 for the difference between M3 F and F3 M transsexuals in an ANOVA for repeated measurements; Table 1 and Fig. 2 ).
Chemokine receptor expression
To investigate to what extent the predominant T H 1 profile found in males would be reflected by phenotypic analyses of T H 1-associated chemokine receptors on the lymphocyte surface, we studied baseline and hormone-induced changes in CCR1, CXCR3, and CCR5 expression. Before hormone administration, no sex differences were found in these chemokine receptor profiles. At baseline, inverse, but weak, correlations were found between the geometric mean surface expression of these chemokine receptors and the IFN␥/IL-4 ratio in both PHA-stimulated supernatants and cytokineproducing T cell numbers (Table 2) .
After estrogen plus antiandrogen administration, but not after testosterone administration, the mean expression of CCR1, CXCR3, and CCR5 increased significantly in both CD8 ϩ and CD8 Ϫ T cells (Table 1 and Fig. 3 ). The fraction of CD3 ϩ T cells expressing CCR1 increased from 2.9% to 5.4%, the fraction that expressed CXCR3 increased from 20.7% to 27.9%, and the fraction that expressed CCR5 increased from 11.9% to 17.9%. After androgen administration to women, no significant effects were found (Table 1 and Fig. 3) .
The surface expressions of CCR1, CXCR3, and CCR5 were strongly and positively intercorrelated ( Table 2 ). Analysis of their individual proportional changes after 4 months showed that, similar to baseline values, these changes were inversely correlated with the T H 1 phenotype, as evaluated by IFN␥/ IL-4 production and intracellular expression ratio by T cells (Table 2 and Fig. 4 ). Concerning CCR5 expression by the helper subset of T cells, the proportional changes correlated inversely not only with the IFN␥/IL-4 ratio, but also with the numbers of TNF␣-producing cells (data not shown).
Ig (sub)class levels
At baseline, significantly higher serum IgG and IgM levels were found in females compared to males (Table 1) . Serum IgG4 and IgE levels were significantly correlated (r ϭ 0.33; P ϭ 0.02). After 4 months of estrogen plus antiandrogen administration to males, only the serum IgA level and the IgG4/IgG ratio decreased slightly (Table 1) . After 4 months of androgen administration to females, serum IgA levels decreased also, but serum IgM levels increased ( Table 1 ). The effects of estrogen plus antiandrogen and androgen treatment were not different after 4 or 12 months when comparing 13 M3 F to 13 F3 M transsexuals with complete data (for all, P Ն 0.10 in ANOVAs for repeated measurements), except for IgE levels (P ϭ 0.03), which decreased in M3 F after 12 months and did not change in F3 M transsexuals (P ϭ 0.04 and P ϭ 0.31, respectively; 12 month data not shown). Sex differences in IgG and IgM were not essentially affected after cross-sex hormone administration (Fig. 5) . Proportional individual changes after 4 months in serum levels of IgM, IgA, and IgG correlated strongly and positively (for all, P Ͻ 0.001). Figure 6 shows the cross-sectional data on serum levels of PRL and TPO-Ab in 186 M3 F transsexuals and 186 agematched male controls. As expected, significantly higher PRL levels were found in M3 F transsexuals compared to the male controls (P Ͻ 0.001, by Wilcoxon's signed ranks test). Fifteen M3 F transsexuals as well as 15 male controls (8.0% for both) had a TPO-Ab titer of 10 U/mL or more. Also, when TPO-Ab levels in M3 F transsexuals were compared to their matched control levels, no significant difference was found (P ϭ 0.23, by Wilcoxon's signed ranks test; Fig. 6 ). The duration of estrogen administration was not associated with TPO-Ab levels in M3 F transsexuals (data not shown). Compared to the age-adjusted prevalences of TPO-Ab in a previous study (9) a significant difference was found between M3 F transsexuals and females (8.0% vs. 14.1%; P Ͻ 0.001, by 2 test), but no significant difference was found between M3 F transsexuals and males (8.0% vs. 6.4%; P ϭ 0.13, by 2 test).
TPO-Ab titers
Discussion
This study of transsexuals undergoing cross-sex hormone treatment, with radical changes in their sex steroid milieus, focused on the effects of sex steroids on parameters of lymphocyte function and serum levels of Ig (sub)classes and TPO-Ab. One of the major phenotypical effects of estrogen administration was the reduction of NK cells numbers. NK cell cytotoxicity is also inhibited by the use of oral contraceptives (45) and during pregnancy, and is inversely associated with serum 17␤-estradiol levels (46) . In vitro, NK cell cytotoxicity is inhibited by diethylstilbestrol (47, 48) and enhanced by the estrogen receptor antagonist tamoxifen (49) . NK cells are essential during host defenses against tumor and viral targets and are believed to prevent the development of autoantibodies by production of the immune system suppressor, transforming-growth factor-␤. The differential effects of estrogens plus antiandrogens vs. testosterone on the number of NK cells and B cells might explain part of the sex difference in the prevalence of various systemic autoimmune diseases (2). The latter pathologies and especially systemic lupus erythematosus seem to be associated with impaired NK cell activity and B cell hyperactivity (50) . Data from animal studies suggested that estrogens enhance CD4 ϩ T cell function, and androgens enhance CD8 ϩ T cell function (51); testosterone administration increased the number of CD8 ϩ T cell in men with Klinefelter's syndrome (52) . Nevertheless, we did not find any change in the number of CD4 ϩ and CD8 ϩ T cells. TPO-Ab were chosen as an example of autoantibodies with a relative high prevalence in females, i.e. 13% compared to 6.1% in males (9) . Although estrogen treatment and castration of male animals result in increased autoantibody levels in murine models (21) (22) (23) (24) (25) , we found a similar frequency (8%) and similar titers of TPO-Ab in orchidectomized males on long term estrogen treatment and in age-matched, male controls. Hyperprolactinemia, induced by long term estrogen therapy and found to be related to TPO-Ab in a previous study (53) , was not associated with elevated TPO-Ab levels. Reports on the in vivo effects of endogenous and exogenous estrogens on IgA, IgG, and IgM levels conflict (54 -56) . In the present study we confirm the finding of higher IgG and IgM levels at baseline in women compared to men (3) (4) (5) (6) . Upon cross-sex hormone administration, however, only minor changes could be observed after 4 and 12 months, and the sex differences before treatment were not reversed. Moreover, the effects on IgA, IgG, and IgM levels of estrogen plus antiandrogen administration in men were largely similar compared to those of testosterone administration in women. Administration of sex steroids may cause body water retention (57, 58) , and the increased plasma volume may have diluted the concentrations of circulating Igs in both treatment groups. This concept is supported by the strong positive correlations between changes in IgA, IgG, and IgM levels. Our data showed that testosterone administration increased the IFN␥/IL-4 production ratio of peripheral blood T cells in women, whereas estrogens plus antiandrogens slightly decreased this ratio in men. Differential effects of sex steroids on cytokine production profiles may be of clinical importance for the outcome of immune-mediated inflammatory disease. For example, the higher risk of developing systemic lupus erythematosus (59) and the increased number of flares (60) in response to pregnancy or estrogen use may be due to potentiation of the T H 2 pathway by estrogens. Estrogen-induced inhibition of T H 1 responsiveness against human papillomavirus infections (61) in women using oral contraception could partially explain the epidemiological association among oral contraception, urogenital infection, and cervical cancer (16) . The risk of cardiovascular disease, preceded by infiltration of macrophages and T cells in the blood vessel wall (62) , may be reduced in women who receive estrogen therapy (63) . It could be hypothesized that a reduced IFN␥ production may contribute to this reduced cardiovascular risk, as illustrated by the reduction of atherosclerotic lesions in IFN␥ receptor knockout mice (64) . As phenotypic markers for T H 1-like T cells, we assessed the expression of the chemokine receptors CCR1, CXCR3, and CCR5 (32) (33) (34) (35) . Unexpectedly, upon estrogen plus antiandrogen administration, but not upon testosterone administration, these chemokine receptors were up-regulated on T cells, which consequently may affect their ability to migrate. Although proinflammatory cytokines can stimulate chemokine production and chemokine receptor expression in vitro (30, 65, 66) , our in vivo data suggested that CCR1, CXCR3, and CCR5 expression is inversely associated with the T H 1/T H 2 balance. In fact, negative correlations were found in PBMC suspensions tested between CCR1, CXCR3, and CCR5 expression and the ratio of IFN␥ to IL-4. However, this phenomenon could not be evaluated at the single cell level, because the expressions of chemokine receptors and cytokines were not determined in a double staining. Apparently, CCR1, CXCR3, and CCR5 expression does not provide a simple phenotypic marker for PBMC propensity toward T H 1 cytokine production. The increased CCR5 expression on helper T cells (11.6% to 18.1%) upon estrogen plus antiandrogen administration may have some implications for AIDS pathogenesis (66) , because CCR5 serves as coreceptor for the entry into macrophages and activated T cells of the macrophage-tropic strain of human immunodeficiency virus-1 (30, 67) .
The observed changes in immune parameters may be caused directly by the administered hormones themselves or may be secondary to complex paracrine responses from adjacent cells and mechanisms affecting other hormones, such as adrenal hormones. We noted in this study that free cortisol, known for its antiinflammatory T H 1-suppressive properties (68) , was increased in 24-h urine samples after estrogen plus antiandrogen administration and was slightly decreased after testosterone administration. Especially estrogens may induce a hyperresponsiveness of the hypothalamic-pituitary-adrenal axis (69, 70) . Expected effects on the secretion of norepinephrine and epinephrine as well as observed effects on cortisol (70), as part of the stress system, could explain part of the observed effects on immune parameters. Additionally, in present and previous (71, 72) studies of cross-sex hormone administration, we observed changes in dehydroepiandrosterone, PRL, GH, insulin-like growth factor I, LH, and FSH, all of which have potentially immunostimulatory properties (41, (73) (74) (75) . Especially, the effects of testosterone may be indirect through changes in other hormones or via dendritic cells (76) , because T cells do not contain testosterone-binding sites (14, 15) .
The interpretation of our results is limited by the inclusion of a relatively small number of subjects in the prospective part of the study and the lack of a placebo group due to the nature of the study population and the treatment indication. Furthermore, the effects of sex steroids in humans depend on the route of administration and the dosage. Our study assessed the effects of androgens in women and of estrogens plus antiandrogens in men. We cannot be sure whether sexappropriate sex steroids would have had similar effects. To date, effects of sex steroids on immune responsiveness have only been studied in vitro (17, 18, 39, 41, 42) . To the best of our knowledge, this is the first experimental study in humans reporting on overall in vivo effects. Table 2. FIG. 5. Individual levels of IgG and IgM (with error bars representing geometric mean and 95% confidence interval of the mean). Serum were obtained from 25 M3 F and 25 F3 M transsexuals at baseline and after 4 months of cross-sex hormone administration, and of 13 M3 F and 13 F3 M transsexuals at 12 months. P values were assessed by Student's t tests using logarithmically transformed data, comparing biological males and females.
In conclusion, estrogens plus antiandrogens in men decreased the number of NK cells and up-regulated the expression of T H 1-associated chemokine receptors. In addition, our data provide evidence for a role of sex steroids as one of the many signals involved in regulation of the T H 1/T H 2 balance in men and women and suggest that testosterone drives peripheral blood T cells down a T H 1 pathway, whereas estrogens may skew differentiation toward T H 2. These changes may be direct or indirect through the effects on other hormones, especially those of the hypothalamicpituitary-adrenal axis.
FIG. 6. Serum PRL levels and TPO-Ab on a logarithmic scale in 186 M3 F transsexuals, after orchidectomy (i.e. castration operation) and treatment with estrogens for 5 yr or more compared to 186 agematched male controls. The reference range for PRL in men is less than 0.3 U/L. Fifteen M3 F transsexuals had a TPO-Ab titer of 10 U/mL or more, which was considered positive compared to that in 15 male controls. P values were assessed by Wilcoxon signed ranks tests for paired samples, comparing each M3 F transsexual with her matched male control.
